:Nicotinyl methylamide
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 428752125
| ImageFile=Methylnicotinamide.png
| ImageSize=150px
| ImageAlt=Skeletal formula of nicotinyl methylamide
| ImageFile1=Nicotinyl methylamide 3D ball.png
| ImageSize1=180
| ImageAlt1=Ball-and-stick model of the nicotinyl methylamide molecule
| PIN=N-Methylpyridine-3-carboxamide
| OtherNames=N-Methylnicotinamide; N-Methylniacinamide
|Section1={{Chembox Identifiers
| Abbreviations=NAN{{Citation needed|date=January 2012}}
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=114-33-0
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X3I82S5L8I
| PubChem=64950
| DrugBank = DB08840
| SMILES=CNC(=O)C1=CN=CC=C1
| InChI = 1/C7H8N2O/c1-8-7(10)6-3-2-4-9-5-6/h2-5H,1H3,(H,8,10)
| InChIKey = ZYVXHFWBYUDDBM-UHFFFAOYAC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C7H8N2O/c1-8-7(10)6-3-2-4-9-5-6/h2-5H,1H3,(H,8,10)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZYVXHFWBYUDDBM-UHFFFAOYSA-N
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 58476
| EINECS = 204-046-4
| MeSHName = C008472
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 64399
}}
|Section2={{Chembox Properties
| C=7 | H=8 | N=2 | O=1
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
}}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =}}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = A05
| ATCCode_suffix = AB01
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| Pregnancy_category =
| Pregnancy_AU =
}}
}}
Nicotinyl methylamide is an experimental drug with no approved indication.{{cite web | url = https://go.drugbank.com/drugs/DB08840 | title = N-methylnicotinamide | work = DrugBank }} It is also a metabolite of nicotinamide (vitamin B3) and is found in urine.{{cite web | url = https://drugs.ncats.io/drug/X3I82S5L8I | title = Nicotinyl methylamide | work = Inxight Drugs | publisher = National Center for Advancing Translational Sciences }}
See also
References
{{Reflist}}
{{Bile and liver therapy}}
{{gastrointestinal-drug-stub}}
{{heterocyclic-stub}}